Erste Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Erste Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01M	Hold	50,000	–	–	0.02%	337
2026 Q1	$2.78M	Hold	50,000	–	–	0.03%	327
2025 Q4	$2.22M	Hold	50,000	–	–	0.02%	342
2025 Q3	$1.95M	Hold	50,000	–	–	0.02%	347
2025 Q2	$1.62M	Hold	50,000	–	–	0.01%	421
2025 Q1	$1.71M	Hold	50,000	–	–	0.02%	325
2024 Q4	$1.94M	Hold	50,000	–	–	0.02%	330
2024 Q3	$1.93M	Hold	50,000	–	–	0.02%	327
2024 Q2	$1.87M	Hold	50,000	–	–	0.02%	309
2024 Q1	$2.15M	Hold	50,000	–	–	0.03%	294
2023 Q4	$2.31M	Buy	50,000 +15,000	+43%	+$530K	0.03%	281
2023 Q3	$1.24M	Hold	35,000	–	–	0.02%	323
2023 Q2	$1.35M	Hold	35,000	–	–	0.02%	327
2023 Q1	$1.25M	Hold	35,000	–	–	0.02%	330
2022 Q4	$1.37M	Hold	35,000	–	–	0.03%	315
2022 Q3	$1.26M	Hold	35,000	–	–	0.03%	326
2022 Q2	$1.08M	Hold	35,000	–	–	0.02%	346
2022 Q1	$1.05M	Hold	35,000	–	–	0.02%	349
2021 Q4	$1.1M	Buy	+35,000	New	+$1.05M	0.02%	347

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Erste Asset Management's XENE Position: Q2 2026 in Review

Erste Asset Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 50,000 shares worth $3.01M. The position accounts for 0.02% of the portfolio, ranked #337.

Erste Asset Management first reported a position in XENE in Q4 2021 and has held it in 19 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Erste Asset Management held 50,000 shares of Xenon Pharmaceuticals worth $3.01M as of Q2 2026.
Erste Asset Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 0.02% of Erste Asset Management's portfolio in Q2 2026, its #337 holding.
Erste Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.